Home / Current Issue / Paper 1722586
Operational Excellence in Saudi Pharmaceutical Manufacturing: Capacity Utilization, Bottleneck Reduction, and Production Performance
Subject area: Science,Engineering and Technology · Area of research: Saudi Pharmaceutical Manufacturing
Abstract
Saudi Arabia is expanding local pharmaceutical manufacturing as part of Vision 2030, the National Industrial Strategy, health-sector transformation, and biotechnology development. As installed capacity grows, the strategic question shifts from whether factories exist to whether regulated manufacturing assets can convert demand into reliable, high-quality output at competitive cost. This review examines operational excellence in Saudi pharmaceutical manufacturing through three connected lenses: capacity utilization, bottleneck reduction, and production performance. An integrative review of recent pharmaceutical operations, Lean Six Sigma, overall equipment effectiveness (OEE), total productive maintenance, production planning, capacity-management, supply-chain, and Pharma 4.0 literature is combined with Saudi policy and regulatory sources. The synthesis shows that pharmaceutical productivity cannot be represented by equipment utilization alone because validated process limits, cleaning and changeovers, material availability, quality-control release, maintenance, workforce capability, deviations, and technology-transfer activities all consume effective capacity. The paper proposes a six-stage operational excellence framework that begins with value-stream and capacity baselining, identifies the system constraint, removes dominant losses through focused improvement, synchronizes planning with finite capacity, integrates quality and reliability into performance control, and then uses digital technologies to sustain gains. A balanced KPI architecture is developed around OEE, schedule adherence, right-first-time performance, batch-release lead time, changeover efficiency, capacity utilization, on-time-in-full delivery, and deviation closure. The framework is translated into a phased 2026–2030 roadmap for Saudi manufacturers. The paper argues that operational excellence should be treated as industrial capability infrastructure: it raises usable capacity without unnecessary capital, strengthens medicine availability, improves the economics of localization, develops local technical skills, and creates a more resilient platform for future biologics and advanced manufacturing.
Keywords
Saudi Vision 2030; pharmaceutical manufacturing; operational excellence; capacity utilization; bottleneck management; overall equipment effectiveness; Lean Six Sigma; production performance; Pharma 4.0; Saudi Arabia
How to cite this paper
@article{1722586,
author = {Mohammed Taqiuddin},
title = {Operational Excellence in Saudi Pharmaceutical Manufacturing: Capacity Utilization, Bottleneck Reduction, and Production Performance},
journal = {Iconic Research And Engineering Journals},
year = {2026},
volume = {10},
number = {2},
pages = {3423-3439},
issn = {2456-8880},
url = {https://www.irejournals.com/formatedpaper/1722586.pdf},
abstract = {Saudi Arabia is expanding local pharmaceutical manufacturing as part of Vision 2030, the National Industrial Strategy, health-sector transformation, and biotechnology development. As installed capacity grows, the strategic question shifts from whether factories exist to whether regulated manufacturing assets can convert demand into reliable, high-quality output at competitive cost. This review examines operational excellence in Saudi pharmaceutical manufacturing through three connected lenses: capacity utilization, bottleneck reduction, and production performance. An integrative review of recent pharmaceutical operations, Lean Six Sigma, overall equipment effectiveness (OEE), total productive maintenance, production planning, capacity-management, supply-chain, and Pharma 4.0 literature is combined with Saudi policy and regulatory sources. The synthesis shows that pharmaceutical productivity cannot be represented by equipment utilization alone because validated process limits, cleaning and changeovers, material availability, quality-control release, maintenance, workforce capability, deviations, and technology-transfer activities all consume effective capacity. The paper proposes a six-stage operational excellence framework that begins with value-stream and capacity baselining, identifies the system constraint, removes dominant losses through focused improvement, synchronizes planning with finite capacity, integrates quality and reliability into performance control, and then uses digital technologies to sustain gains. A balanced KPI architecture is developed around OEE, schedule adherence, right-first-time performance, batch-release lead time, changeover efficiency, capacity utilization, on-time-in-full delivery, and deviation closure. The framework is translated into a phased 2026–2030 roadmap for Saudi manufacturers. The paper argues that operational excellence should be treated as industrial capability infrastructure: it raises usable capacity without unnecessary capital, strengthens medicine availability, improves the economics of localization, develops local technical skills, and creates a more resilient platform for future biologics and advanced manufacturing.},
keywords = {Saudi Vision 2030; pharmaceutical manufacturing; operational excellence; capacity utilization; bottleneck management; overall equipment effectiveness; Lean Six Sigma; production performance; Pharma 4.0; Saudi Arabia},
month = {August},
}